Vericel Corp. (VCEL)

[commoncentsinvestor]

Biotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel, and Biogen

Last update: 01/03/2017 4:15:14 am


NEW YORK, March 1, 2017 /PRNewswire/ --

Four Biotech equities have been lined up by Stock-Callers.com today, and they are Immunomedics Inc. (NASDAQ: IMMU), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Vericel Corp. (NASDAQ: VCEL), and Biogen Inc. (NASDAQ: BIIB). These firms are part of the Healthcare sector, which extended its declines in afternoon trade on Tuesday, February 28(th) , 2017, with the NYSE Health Care Index falling about 0.5%, while shares of health care companies in the S&P 500 were down more than 0.4% as a group.

Vericel

Cambridge, Massachusetts headquartered Vericel Corp.'s stock finished the day 1.69% higher at $3.00 with a total trading volume of 219,711 shares. The Company's shares have gained 15.38% in the last one month and 17.65% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 3.66% and 18.35%, respectively. Additionally, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, have an RSI of 57.20.

On February 21(st) , 2017, Vericel announced that the US Food and Drug Administration has designated the investigation of ixmyelocel-T for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Track Development Program. Register for free on Stock-Callers.com and download the PDF research report on VCEL at:

http://stock-callers.com/registration/?symbol=VCEL